A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
for Dermatitis Atopic
Drug: Amlitelimab
42 locations incl. Birmingham
Sponsor: Sanofi
Sex: All·Age: 12+
Code: NCT06241118·Phase 3·Recruiting